PARP1 and non-small cell lung carcinoma: Herein, we report our evaluation of FA deficiency in a series of tumors from patients with NSCLC and the response of lung cancer cells with reduced FANCD2 expression (FANCD2 knock-down cell) to treatment with inhibitors of PARP, CHK1, and BCL-2/XL.